Opportunity Alert – AC-160105-085 – TAKEDA-01
Date Sourced: March 7, 2016
Category: Customer Opportunity
Status: Qualifying
Potential (High-Moderate-Low): High
Add to SFA (Y/N): TBD
Client Action Required (Y/N): No
Opportunity:
Takeda Pharmaceutical is among the top 15 pharmaceutical companies in the
United States with global clinical trial operations. They have a robust
pipeline of compounds in multiple therapeutic areas including: metabolic
and cardiovascular diseases, central nervous system, respiratory and
immunology, oncology and general medicine.
Website: www.takeda.us/
Summary:
1. March 7, 1016 – Contacted Ryan McClellan, Takeda Phamaceutical
Associate Director, Analytics and Technology Medical and Scientific
Affairs, US Region with an invite to the CleverCap Med Adherence CxO
Briefing on March 22, 2016. Responded with interest and introduced a Takeda
Sr. Director of US Medical Affairs, who is focused on the med adherence
space.
2. March 10, 2016 – Mike Abbadessa, Pharm. D., Takeda Sr Dir Sci Strat &
Ops, Medical Affairs, US Region followed-up to confirm interest in
CleverCap, but not available for presentation until early April.
3. April 4, 2016 – Scheduling a CleverCap presentation to both Ryan
and Mike. Potentially looking to participate remotely while I am in
Chicago (mid-April).
Forward Statements:
Patriot Labs has several stakeholder contacts within Takeda that can be
pursued, including the VP of Clinical Outsourcing who is directly involved
with assessing the protocols for late phase clinical trials. Additional
updates will be made leading up to mid-April meeting.
End.
Return to Listing
COMMENT FORM.
Comments